The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
